ActiveAtlas Opportunity Score 89/100
NIH/CDC/FDA Parent SBIR — PA-27-100
Open NIH/CDC/FDA Parent SBIR opportunity for U.S. small businesses conducting health-related R&D. The next standard application date is January 5, 2027 at 5:00 PM applicant-local time. Strong potential for legitimate N9+ product R&D or validation, subject to SBIR eligibility and institute fit.
FundingAward budgets vary by participating NIH/CDC/FDA component and phase. The revised announcement lists component-specific NIH limits; for example, NIDDK normally allows up to $400,000 Phase I and $2.5 million Phase II. Applicants must follow the applicable component and SBA budget guidance.
DeadlineNext standard due date: January 5, 2027 at 5:00 PM local time of the applicant organization. Subsequent standard due date: April 5, 2027 at 5:00 PM local time. Announcement expiration: April 6, 2027.
Last verifiedSeptember 29, 2026
Required next actionDefine a specific hypothesis-driven SBIR project, confirm the participating NIH, CDC, or FDA component and phase, verify U.S. small-business and PI eligibility plus required registrations, review component-specific budget and clinical-trial rules, and prepare for the January 5, 2027 standard due date at 5:00 PM local time of the applicant organization unless a component-specific instruction controls.
Broad Eligibility
Only eligible United States small business concerns may apply. The concern must satisfy SBA SBIR ownership/control and size requirements, including no more than 500 employees including affiliates, plus all required federal and NIH registrations. Foreign organizations are not eligible.
Atlas Analysis
Atlas Opportunity Score 89/100. Active parent SBIR opportunity for eligible U.S. small businesses pursuing mission-aligned research and development under participating NIH, CDC, and FDA components. PA-27-100 expires April 6, 2027 and uses standard SBIR due dates. The next standard due date is January 5, 2027 at 5:00 PM local time of the applicant organization, followed by April 5, 2027. Applicants should confirm the participating component, scientific fit, phase, budget guidance, PI and employment rules, registrations, and any component-specific limitations before submission.
NIH, CDC, and FDA are accepting applications under PA-27-100, the Parent Small Business Innovation Research (SBIR) R43/R44 funding opportunity for eligible U.S. small business concerns developing health-related commercial technologies.
Next standard deadline: January 5, 2027 at 5:00 PM local time of the applicant organization. A subsequent standard deadline is April 5, 2027 at 5:00 PM applicant-local time; the announcement expires April 6, 2027. No late applications are accepted.
The NOFO accepts Phase I, Phase II, NIH Direct to Phase II, and NIH Fast-Track applications. Award budgets vary by participating component; for example, the revised announcement lists NIDDK normal NIH-component limits of $400,000 for Phase I and $2.5 million for Phase II, while other components use different limits or SBA guidelines.
Atlas fit: Strong for a legitimate N9+ R&D, validation, evidence-generation, or product-development project that advances a commercial healthcare technology. This is not a device-purchase grant and should not be used for routine deployment or sales. Only qualifying U.S. small business concerns may apply, and the small business must perform the majority of the research or analytical effort.
New NIH highlighted topic, September 9, 2026: NIH is encouraging investigator-initiated research on biology- and physics-informed explainable artificial intelligence across the lifespan. NIH states this is a highlighted topic rather than a stand-alone NOFO and directs applicants to use an appropriate Parent Funding Announcement or other broad opportunity. For Atlas, this creates an additional research angle under PA-27-100 only where an N9+ project can credibly use mechanistically grounded explainable AI to advance understanding or prediction of health and disease across the life course. It does not change SBIR eligibility or make ordinary device deployment responsive.
From Funding to Implementation · Remote Monitoring Solution
Connect grant funding to a broader remote-care strategy.
Dr. Miltie combines connected monitoring and virtual examination capabilities so funded programs can support longitudinal care while giving clinicians more context when a remote encounter requires assessment beyond a video visit.
Source verificationOfficial government source · simpler.grants.govAtlas last verified this record September 29, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
